Highlights

  • Cochlear Limited (ASX:COH) reported FY26 sales revenue of AUD 2,343.4mn, down 1% as reported but up 2% in constant currency.
  • Underlying net profit declined 22% YoY to AUD 322.4mn; statutory net profit fell to AUD 147.3mn.
  • Cochlear implant units increased 5% YoY to 56,692, although implant revenue was flat in constant currency.
  • FY27 guidance targets underlying net profit of AUD 330–350mn and low-single-digit constant-currency sales growth.

Cochlear Limited develops implantable hearing devices and sound processors for people with hearing loss, serving recipients and clinicians across international markets. Following its FY26 results and the rollout of the Nucleus Nexa system, the share price cited for 27 October 2026 was AUD 139.82. Cochlear Limited (ASX:COH) entered FY27 after reporting increased implant unit volumes but lower underlying earnings, making reimbursement conditions, product adoption and operating costs central to its next reporting period.

Company Business

Cochlear Limited (ASX:COH) operates across three product and service groups: cochlear implants, services and acoustics. Its implant systems provide electrical hearing stimulation, while services include replacement sound processors, accessories and ongoing recipient support. The acoustics portfolio includes bone-conduction hearing systems. Its products reach customers through healthcare professionals, clinics and health systems, and the company reports exposure across the Americas, Europe, the Middle East, Africa and Asia Pacific.

The economics of the business depend on patients reaching specialist assessment, eligibility decisions, reimbursement approval and surgery. After implantation, sound processor replacements and other services create a further source of revenue. Cochlear also allocates funding to research and development, including future implant technology, software and clinical support capabilities.

Recent Development

In August 2026, Cochlear Limited (ASX:COH) released its results for the year ended 30 June 2026. Implant volumes reached 56,692 units, a 5% annual increase, although a higher proportion of lower-priced emerging-market units contributed to flat implant revenue in constant currency. Developed-market revenue rose 1% in constant currency. The company identified surgery delays, reimbursement processes and uneven regional conditions as factors affecting demand conversion.

The Nucleus Nexa system was a major FY26 product milestone. Cochlear reported that Nexa accounted for more than 95% of implant sales in developed markets by June 2026 and supported an average 3% price increase. It also continued work on totally implantable technology and a drug-eluting electrode, while restructuring activities sought to reduce fixed costs and redirect resources toward selected growth programs.

Services revenue increased 6% in constant currency, with developed-market growth supported by replacement sound processor demand. Acoustics revenue increased 1% in constant currency, with second-half improvement following a weaker first half. These different patterns illustrate why implant numbers alone do not determine consolidated revenue and earnings.

Financial Performance and Sector Context

Cochlear Limited (ASX:COH) recorded FY26 sales revenue of AUD 2,343.4mn, compared with AUD 2,355.8mn in FY25, a 1% reported decline and 2% constant-currency increase. Cochlear implant revenue was AUD 1,435.2mn versus AUD 1,470.2mn, while services revenue advanced to AUD 634.9mn from AUD 609.2mn. Acoustics revenue was AUD 273.3mn against AUD 276.4mn a year earlier.

Underlying EBIT declined 22% to AUD 432.6mn from AUD 554.0mn. Underlying net profit fell to AUD 322.4mn from AUD 414.5mn, while statutory net profit decreased 62% to AUD 147.3mn. The gross margin narrowed to 71% from 74%. The company attributed pressure to sales mix, manufacturing variances and currency movements, alongside transitional expenditure. Research and development expense increased 15% to AUD 323.2mn, representing approximately 14% of sales revenue.

The board declared FY26 dividends of AUD 3.45 per share, compared with AUD 4.30 for FY25. At 30 June 2026, cash and cash equivalents were AUD 187.7mn, compared with AUD 275.7mn a year earlier. For the healthcare-device sector, hospital scheduling, payer decisions and clinical referral pathways affect the timing of procedures, while foreign exchange movements affect reported figures for companies selling internationally.

Risks to Consider

Cochlear Limited (ASX:COH) faces variability in patient referrals, insurance authorisations, hospital capacity and implant procedure timing. Lower-priced product and geographic mixes may constrain gross margins even as unit sales rise. Manufacturing utilisation, restructuring execution and sustained research expenditure create additional cost considerations. Competition in hearing technologies, regional reimbursement changes and currency movements can also influence revenue and profitability. Emerging product programs carry development and regulatory risks.

What to Watch Next

For FY27, Cochlear Limited (ASX:COH) guided to low-single-digit constant-currency sales growth and underlying net profit of AUD 330–350mn. The guidance assumes gradual improvement in developed-market implants, cost discipline and targeted investment. Subsequent disclosures will clarify whether Nexa adoption is reflected in revenue, how replacement processor demand develops and whether operational changes improve margins. Investors can also monitor research milestones, reimbursement conditions and the half-year financial report.

Key Insights

FY26 combined higher implant units and services growth with lower reported sales, reduced gross margin and a 22% decline in underlying net profit. Cochlear Limited (ASX:COH) has set FY27 profit guidance above its FY26 outcome while continuing its product and clinical access initiatives. The principal monitoring points are sales mix, developed-market implantation activity, fixed-cost changes and the conversion of device adoption into earnings.